Results 31 to 40 of about 3,446,938 (405)

Severe asthma features in children: A case-control online survey [PDF]

, 2016
Background: Very few studies have explored the distinguishing features of severe asthma in childhood in Europe, and only one study was conducted in Southern Europe.
Aralla, R, Baraldi, E, Benedictis, F, Berardi, M, Brunetti, L, Cardinale, F, Cazzato, S, Cutrera, R, Fenu, G, FERRANTE, Giuliana, LA GRUTTA, Stefania, Lombardi, E, Montella, S, Palmo, E, Piacentini, G, Pillo, S, Rusconi, F., SANTAMARIA, Francesca, Ullmann, N   +18 more
core   +3 more sources

Application of an algorithm to analyze patterns of intermittent oral corticosteroid use in asthma

npj Primary Care Respiratory Medicine, 2023
An algorithm to describe patterns of intermittent oral corticosteroid use in the UK (n = 476,167) found that one-third of patients receiving intermittent oral corticosteroids for asthma only had short gaps (
John Haughney, Trung N. Tran, Heath Heatley, Arnaud Bourdin, Andrew Menzies-Gow, David J. Jackson, Ekaterina Maslova, Jatin Chapaneri, Derek Skinner, Victoria Carter, Jeffrey Shi Kai Chan, David Price   +11 more
doaj   +1 more source

The Portuguese Severe Asthma Registry: Development, Features, and Data Sharing Policies [PDF]

, 2018
The Portuguese Severe Asthma Registry (Registo de Asma Grave Portugal, RAG) was developed by an open collaborative network of asthma specialists. RAG collects data from adults and pediatric severe asthma patients that despite treatment optimization and ...
Arrobas, A, Costa, A, Costa, C, et al., Costa, T, Drummond, M, Farinha, P, Fernandes, B, Ferreira, A, Fonseca, JA, Longo, C, Loureiro, C, Mendes, A, Pardal, C, Pereira, AM, Rocha, P, Soares, J, Sokolova, A, Sá-Sousa A1, A, Todo-Bom, A, Videira, W   +19 more
core   +1 more source

Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study)

BMC Pulmonary Medicine, 2021
Background Benralizumab, a monoclonal antibody targeting the human interleukin-5 (IL-5) receptor (IL-5R), was used before marketing authorisation in Spain in a real world setting as part of an early-access programme (EAP) to treat patients with severe ...
Eva Martínez-Moragón, Ismael García-Moguel, Javier Nuevo, Gustavo Resler, ORBE study investigators   +4 more
doaj   +1 more source

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma

Allergy. European Journal of Allergy and Clinical Immunology, 2020
Five biologicals have been approved for severe eosinophilic asthma, a well‐recognized phenotype. Systematic reviews (SR) evaluated the efficacy and safety of benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab (alphabetical order) compared to
I. Agache, Jessica Beltran, C. Akdis, M. Akdiş, C. Canelo-Aybar, W. Canonica, T. Casale, T. Chivato, J. Corren, S. D. Del Giacco, T. Eiwegger, D. Firinu, J. Gern, E. Hamelmann, N. Hanania, M. Mäkelä, I. H. Martín, Parameswaran Nair, L. O’Mahony, N. Papadopoulos, A. Papi, Hae‐Sim Park, L. A. Pérez de Llano, M. Posso, Claudio Rocha, S. Quirce, J. Sastre, M. Shamji, Yang Song, Corinna Steiner, J. Schwarze, P. Alonso-Coello, Ó. Palomares, M. Jutel   +33 more
semanticscholar   +1 more source

Depiction of Major Mite Allergens in Severe Allergic Rhinitis with High Mite Perennial Exposure

Turkish Archives of Otorhinolaryngology, 2020
Objective: Airway diseases, including allergic rhinitis, are prompted by specific IgE antibodies against airborne allergens and notably those derived from mites.
Ruperto González-Pérez, Paloma Poza-Guedes, Fernando Pineda, Miriam Castillo   +3 more
doaj   +1 more source

Efficacy and Safety of Dupilumab in Glucocorticoid‐Dependent Severe Asthma

New England Journal of Medicine, 2018
BACKGROUND Dupilumab is a fully human anti–interleukin‐4 receptor α monoclonal antibody that blocks both interleukin‐4 and interleukin‐13 signaling. Its effectiveness in reducing oral glucocorticoid use in patients with severe asthma while maintaining ...
K. Rabe, Parameswaran Nair, G. Brusselle, J. Maspero, M. Castro, L. Sher, Hongjie Zhu, J. Hamilton, B. Swanson, A. Khan, J. Chao, H. Staudinger, G. Pirozzi, C. Antoni, N. Amin, M. Ruddy, B. Akinlade, N. Graham, N. Stahl, G. Yancopoulos, A. Teper   +20 more
semanticscholar   +1 more source

Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era

Thorax, 2020
Background The UK Severe Asthma Registry (UKSAR) is the world’s largest national severe asthma registry collecting standardised data on referrals to UK specialist services.
D. Jackson, J. Busby, P. Pfeffer, A. Menzies-Gow, T. Brown, R. Gore, M. Doherty, A. Mansur, S. Message, R. Niven, M. Patel, L. Heaney   +11 more
semanticscholar   +1 more source

Critical evaluation of asthma biomarkers in clinical practice

Frontiers in Medicine, 2022
The advent of personalized medicine has revolutionized the whole approach to the management of asthma, representing the essential basis for future developments.
Giuseppe Guida, Diego Bagnasco, Vitina Carriero, Francesca Bertolini, Fabio Luigi Massimo Ricciardolo, Stefania Nicola, Luisa Brussino, Emanuele Nappi, Emanuele Nappi, Giovanni Paoletti, Giovanni Paoletti, Giorgio Walter Canonica, Giorgio Walter Canonica, Enrico Heffler, Enrico Heffler   +14 more
doaj   +1 more source

Clinical utility of fractional exhaled nitric oxide in severe asthma management

European Respiratory Journal, 2020
Asthma is a chronic inflammatory disease of the airways, affecting over 350 million people worldwide and placing a significant burden on healthcare providers and wider society.
A. Menzies-Gow, A. Mansur, C. Brightling
semanticscholar   +1 more source